Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 Study With an Open-label Dose Escalation Phase Followed by a Randomized, Double-blind Phase of SLN124 in Patients With Polycythemia Vera

Next Previous
X
Search
Trial Profile

Phase 1/2 Study With an Open-label Dose Escalation Phase Followed by a Randomized, Double-blind Phase of SLN124 in Patients With Polycythemia Vera

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Jun 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Divesiran (Primary)
  • Indications Polycythaemia vera
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SANRECO; SLN
  • Sponsors Silence Therapeutics

    • Most Recent Events

    • 27 Jun 2024 According to a Silence Therapeutics media release, As of today, Silence has enrolled 21 patients in the SANRECO study and the Company anticipates closing enrollment at the end of this month. Full results are expected to be presented at a scientific meeting later this year.
    • 27 Jun 2024 According to a Silence Therapeutics media release, company is looking forward to advancing development with a phase 2 start planned by year-end
    • 27 Jun 2024 Results ( from phase 1; data cut-off date of March 29, 2024, n=16) presented in the Silence Therapeutics Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top